Charles River Laboratories International, Inc. (CRL)
| Market Cap | 8.23B |
| Revenue (ttm) | 4.02B |
| Net Income (ttm) | -144.34M |
| Shares Out | 49.34M |
| EPS (ttm) | -2.91 |
| PE Ratio | n/a |
| Forward PE | 15.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 435,173 |
| Open | 170.42 |
| Previous Close | 171.23 |
| Day's Range | 165.08 - 170.95 |
| 52-Week Range | 112.39 - 228.88 |
| Beta | 1.62 |
| Analysts | Buy |
| Price Target | 198.27 (+18.87%) |
| Earnings Date | May 7, 2026 |
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $198.27, which is an increase of 18.87% from the latest price.
News
Charles River Associates (CRA) to Host First-Quarter Fiscal 2026 Financial Results Conference Call on May 7
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the company will webcast...
Charles River Highlights Effectiveness of VCGs in Toxicology
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has shared the results of a retrospective analysis in Regulatory Toxicology and Pharmacolo...
Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call.
Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with the American Heart Association, the world's leading n...
NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 6, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...
Charles River Laboratories International Transcript: Barclays 28th Annual Global Healthcare Conference
Demand is rebounding as biotech funding improves, with bookings and backlog showing positive trends. Technology and AI are seen as long-term complements, while recent acquisitions and divestitures sharpen focus on core strengths and margin improvement. China’s innovation and market size present both competition and opportunity.
Charles River Laboratories International Transcript: TD Cowen 46th Annual Health Care Conference
Leadership transition is underway with a focus on growth, modernization, and portfolio optimization. Improved biotech funding and strategic acquisitions support a positive outlook, while AI and digital initiatives aim to boost efficiency. Margin improvements and stable core segments underpin future growth.
Charles River Laboratories to Present at TD Cowen and Barclays Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at TD Cowen and Barclays Conferences.
Charles River raises annual profit view as it sells underperforming assets
Contract drug developer Charles River Laboratories raised its 2026 profit forecast on Wednesday, after it announced the sales of some underperforming assets to peer IQVIA and private equity firm GI Pa...
Charles River Laboratories Provides Update on Planned Divestitures
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Update on Planned Divestitures.
Charles River Laboratories International Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 results met the upper end of guidance despite organic revenue declines, with DSA bookings and backlog improving on stronger biotech funding. 2026 guidance calls for flat to slightly negative organic revenue, margin expansion from acquisitions, and a return to DSA growth in H2 if demand trends persist.
Charles River forecasts upbeat 2026 profit on improved demand for drug development services
Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and development services ...
Charles River Laboratories Announces Executive Appointments
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Executive Appointments.
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance.
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your right...
Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call.
Charles River Enters Manufacturing Collaboration with Gazi University
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Gazi University Faculty of Medicine, today announced a gene therapy contract developme...
Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Charles River Laboratories International Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong market leadership and improved financials were highlighted, with strategic divestitures and acquisitions set to boost margins and supply chain stability. Demand is rebounding, especially in biotech, and innovation in non-animal technologies and digital tools is a key focus.
Charles River to buy Cambodia-based monkey supplier for $510 million
Charles River Laboratories said on Monday it would buy one of its major suppliers of non-human primates for about $510 million as the contract research firm seeks greater control over procurement of t...
Charles River Laboratories Provides Business Updates
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Business Updates.
Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan.
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Laun...
T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform
BOSTON--(BUSINESS WIRE)--Charles River Development, a State Street Company, announced today the expansion of its relationship with T. Rowe Price through the migration to the SaaS-deployed Charles Rive...